Literature DB >> 21689212

Haemophilia utilization group study - Part Va (HUGS Va): design, methods and baseline data.

Z-Y Zhou1, J Wu, J Baker, R Curtis, A Forsberg, H Huszti, M Koerper, M Lou, R Miller, K Parish, B Riske, A Shapiro, M Ullman, K Johnson.   

Abstract

To describe the study design, procedures and baseline characteristics of the Haemophilia Utilization Group Study - Part Va (HUGS Va), a US multi-center observational study evaluating the cost of care and burden of illness in persons with factor VIII deficiency. Patients with factor VIII level ≤ 30%, age 2-64 years, receiving treatment at one of six federally supported haemophilia treatment centres (HTCs) were enrolled in the study. Participants completed an initial interview including questions on socio-demographical characteristics, health insurance status, co-morbidities, access to care, haemophilia treatment regimen, factor utilization, self-reported joint pain and motion limitation and health-related quality of life. A periodic follow-up survey collected data regarding time lost from usual activities, disability days, health care utilization and outcomes of care. HTC clinicians documented participants' baseline clinical characteristics and pharmacy dispensing records for 2 years. Between July 2005 and July 2007, 329 participants were enrolled. Average age was 9.7 years for children and 33.5 years for adults; two-thirds had severe haemophilia. The distributions of age, marital status, education level and barriers to haemophilia care were relatively consistent across haemophilic severity categories. Differences were found in participants' employment status, insurance status and income. Overall, children with haemophilia had quality of life scores comparable to healthy counterparts. Adults had significantly lower physical functioning than the general US population. As one of the largest economic studies of haemophilia care, HUGS Va will provide detailed information regarding the burden of illness and health care utilization in the US haemophilia A population.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21689212     DOI: 10.1111/j.1365-2516.2011.02595.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  4 in total

1.  Longitudinal changes in health-related quality of life for chronic diseases: an example in hemophilia A.

Authors:  Jiat-Ling Poon; Jason N Doctor; Michael B Nichol
Journal:  J Gen Intern Med       Date:  2014-08       Impact factor: 5.128

2.  Comorbidities, Health-Related Quality of Life, Health-care Utilization in Older Persons with Hemophilia-Hematology Utilization Group Study Part VII (HUGS VII).

Authors:  Randall Curtis; Marilyn Manco-Johnson; Barbara A Konkle; Roshni Kulkarni; Joanne Wu; Judith R Baker; Megan Ullman; Duc Quang Tran; Michael B Nichol
Journal:  J Blood Med       Date:  2022-05-09

3.  Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s.

Authors:  Kathelijn Fischer; Katarina Steen Carlsson; Pia Petrini; Margareta Holmström; Rolf Ljung; H Marijke van den Berg; Erik Berntorp
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

4.  Burden of mild haemophilia A: Systematic literature review.

Authors:  Flora Peyvandi; Fatemeh Tavakkoli; Diana Frame; Jennifer Quinn; Benjamin Kim; Adebayo Lawal; Mimi C Lee; Wing Y Wong
Journal:  Haemophilia       Date:  2019-07-11       Impact factor: 4.287

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.